Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial

Jesus San Miguel, Katja Weisel, Philippe Moreau, Martha Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Andrew Belch, Antonio Palumbo, Stephen Schey, Pieter SonneveldXin Yu, Lars Sternas, Christian Jacques, Mohamed Zaki, Meletios Dimopoulos

Research output: Contribution to journalArticlepeer-review

529 Scopus citations

Fingerprint Dive into the research topics of 'Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences